Secretin-induced Duodenal Aspirate of Pancreatic Juice (SIDA): Utility of Commercial Genetic Analysis.

摘要: Background Secretin-induced duodenal aspiration (SIDA) of pancreatic duct fluid has been proposed for neoplasm screening in very high-risk patients. We sought to determine the clinical yield and safety commercially-analyzed SIDA samples patients at moderately elevated risk. Patients methods A prospectively maintained institutional database DNA profiles was retrospectively reviewed. Results Fifty-seven underwent testing, most commonly intraductal papillary mucinous neoplasms (n=43) not otherwise specified solitary cysts (n=9). mutation low compared 37 concomitant endoscopic ultrasound-guided fine needle (EUS-FNA) fluid: KRAS (2.5% vs. 40.0%), GNAS (2.6% 11.1%) allelic loss heterozygosity (3.1% 0%). undergoing alone experienced no complications while 3 with EUS-FNA had post-procedural pancreatitis. Conclusion The genetic relatively a risk cohort. testing may have better profile than EUS-FNA.